S&P 500 cuts losses as Nvidia climbs ahead of results
Christine Ring, the Chief Legal Officer of Nurix Therapeutics, Inc. (NASDAQ:NRIX), made notable transactions involving the company's common stock on January 2, 2025. According to the recently filed SEC Form 4, Ring sold 5,760 shares of Nurix Therapeutics at a weighted average price of $19.4956 per share, resulting in a total sale value of approximately $112,294. The transaction comes as the stock, currently valued at $1.39 billion by market cap, has shown remarkable strength with a 90.9% return over the past year. InvestingPro analysis indicates the stock is trading slightly above its Fair Value.
In addition to the sale, Ring also exercised stock options to acquire 5,760 shares at a price of $1.86 per share, which was part of a Rule 10b5-1 trading plan previously adopted by her. Following these transactions, Ring holds 28,084 shares of Nurix Therapeutics directly.
The sales were executed within a price range of $18.91 to $19.73 per share. Ring has committed to providing detailed information about the specific number of shares sold at each price upon request.
In other recent news, Nurix Therapeutics has seen significant advancements in its clinical developments. The U.S. Food and Drug Administration granted Fast Track designation to the company's drug candidate NX-5948 for treatment of adult patients with relapsed or refractory Waldenstrom’s macroglobulinemia. The European Medicines Agency also granted PRIME designation to NX-5948 for the treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.
On the financial front, Nurix plans to sell up to $300 million of its common stock through an equity distribution agreement with investment bank Piper Sandler & Co. In terms of analyst ratings, H.C. Wainwright has increased its 12-month price target for Nurix from $30 to $35 and maintained a Buy rating. BMO Capital Markets and UBS also initiated coverage on Nurix with a Buy rating, expressing confidence in the potential of NX-5948.
Finally, Anil Kapur, a veteran in the pharmaceutical sector, has been appointed to Nurix's board of directors. This addition is expected to bring valuable strategic insights as the company prepares for pivotal clinical trials in 2025.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.